Trial Profile
Study of the Pharmacodynamics of NGM282 on Colonic Transit, Bile Acid Homeostasis, and Fecal Fat in Subjects With Functional Constipation and Healthy Individuals
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 May 2018
Price :
$35
*
At a glance
- Drugs Aldafermin (Primary)
- Indications Constipation
- Focus Therapeutic Use
- Sponsors NGM Biopharmaceuticals
- 02 May 2018 Primary endpoint (Colonic transit as measured by geometric center at 48 h) has been met, according to results published in the American Journal of Gastroenterology.
- 02 May 2018 Results (n=31) assessing effect of NGM282 on colonic transit, bile acid homeostasis, and fecal fat in subjects with functional constipation and healthy individuals, were published in the American Journal of Gastroenterology.
- 09 May 2017 Results presented at the Digestive Disease Week 2017